139 related articles for article (PubMed ID: 35545174)
21. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
22. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
23. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
24. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
Wong W; Wu N; Gupta R; Mansfield AS
Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067
[TBL] [Abstract][Full Text] [Related]
25. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
26. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
28. Access denied: The relationship between patient insurance status and access to high-volume hospitals.
Nabi J; Tully KH; Cole AP; Marchese M; Cone EB; Melnitchouk N; Kibel AS; Trinh QD
Cancer; 2021 Feb; 127(4):577-585. PubMed ID: 33084023
[TBL] [Abstract][Full Text] [Related]
29. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract][Full Text] [Related]
30. Racial and ethnic inequities of palliative care use among advanced Non-Small cell lung cancer patients in the US.
Islam JY; Braithwaite D; Zhang D; Guo Y; Tailor TD; Akinyemiju T
Cancer Med; 2023 Apr; 12(7):8567-8580. PubMed ID: 36533434
[TBL] [Abstract][Full Text] [Related]
31. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
[TBL] [Abstract][Full Text] [Related]
32. Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings.
Unger JM; Blanke CD; LeBlanc M; Barlow WE; Vaidya R; Ramsey SD; Hershman DL
JAMA Netw Open; 2020 Apr; 3(4):e203842. PubMed ID: 32352530
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Management and Outcomes of Acute Heart Failure Hospitalization in Medicaid Beneficiaries Versus Privately Insured Individuals.
Thakkar S; Majmundar M; Kumar A; Kansara T; Adalja D; Ilyas I; Desai R; Doshi R
Am J Cardiol; 2020 Apr; 125(7):1063-1068. PubMed ID: 32146925
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
[TBL] [Abstract][Full Text] [Related]
35. Disparities in the outcomes of lumbar spinal stenosis surgery based on insurance status.
Lad SP; Huang KT; Bagley JH; Hazzard MA; Babu R; Owens TR; Ugiliweneza B; Patil CG; Boakye M
Spine (Phila Pa 1976); 2013 Jun; 38(13):1119-27. PubMed ID: 23354106
[TBL] [Abstract][Full Text] [Related]
36. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
Mileham KF; Schenkel C; Bruinooge SS; Freeman-Daily J; Basu Roy U; Moore A; Smith RA; Garrett-Mayer E; Rosenthal L; Garon EB; Johnson BE; Osarogiagbon RU; Jalal S; Virani S; Weber Redman M; Silvestri GA
Cancer Med; 2022 Jan; 11(2):530-538. PubMed ID: 34921524
[TBL] [Abstract][Full Text] [Related]
37. Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes.
Inverso G; Mahal BA; Aizer AA; Donoff RB; Chuang SK
J Oral Maxillofac Surg; 2016 Jun; 74(6):1241-7. PubMed ID: 26851312
[TBL] [Abstract][Full Text] [Related]
38. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
[TBL] [Abstract][Full Text] [Related]
39. The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years.
Fletcher SA; Cole AP; Lu C; Marchese M; Krimphove MJ; Friedlander DF; Mossanen M; Kilbridge KL; Kibel AS; Trinh QD
Cancer; 2020 Feb; 126(3):496-505. PubMed ID: 31626340
[TBL] [Abstract][Full Text] [Related]
40. The effect of insurance status on overall survival among children and adolescents with cancer.
Wang X; Ojha RP; Partap S; Johnson KJ
Int J Epidemiol; 2020 Aug; 49(4):1366-1377. PubMed ID: 32572489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
